Cientista no computador

Spontaneous Tumor Model for Drug Efficacy Research

Increase the predictivity of drug discovery


Companion animals can be used as a informative model in the preclinical development and discovery of novel cancer treatment.
Studies in dogs provide guidance for conducting similar investigation in human patients.
This model helps to evaluate the efficacy  and feasibility of new compounds and can inform the GO/NO-GO decision in clinical drug development.

Selected compound with anti-cancer activity demonstrated in vitro and mice studies 

We design and conduct 

companion animals trials in

our veterinary international

practices network

High predictivity

efficacy results

Go/No-Go Decision

Examples of Preclinical Investigation in Companion Animals 


FDA approved for human use

Companion animals trial suggest that acalabrutinib is safe and exhibits activity in canine B-cell lymphoma patients and support the use of canine lymphoma as a relevant model for human non-Hodgkin lymphoma (NHL).


Phase II human trial completed

Demonstration of target inhibition in companion animal trial. Studies in dogs were used as a proof of target and refined measure of drug exposure.


FDA approved for human use

Validation of biomarker test for use in human trials; dose modulation. Companion animals trial demonstrated efficacy and surrogate endpoint.


Phase III human trials

Proof-of-target for IND application; defined PK/PD relationship. Determined toxicity, biomarkers, and biologic activity


Phase I human trials ongoing

PK, PD, efficacy and toxicity studies were conducted in companion animals naturally affected with malignant melanoma

Sulphonamide PAC-1 or SPAC-1

Human trials were not conducted

Decision was made to not move forward with human studies based on companion animals trials results.


Phase I human trials ongoing

Assessed single-agent activity and toxicity for development of tolerable dosing regimen.


Phase I human trials ongoing

Determined dosing regimen and supportive care protocols in companion animals. Identified adverse events, dose, and regimen.

LMP400, LMP776 and LMP744

Phase I human trials ongoing

Phase I study for lymphoma-bearing dogs to evaluate differential efficacy, pharmacodynamics, toxicology, and pharmacokinetics, supporting their further clinical development.


Phase III human trials ongoing

Studies in companion animals confirmed inhibition and tumor response. Important proof of concept study. Masitinib is EMA-approved for veterinary use.

Are you having problem to translate results from mice to human?

Less than 8% of compounds tested in mice models pass successfully human phase I clinical trial
Learn how our In vivo Efficacy Model for Cancer Research can increase the predictivity of drug discovery

Woman chemist testing new formula on lit

Sign up to stay up-to-date with Ridge news


Get in touch

Company Team


Lucas Rodrigues, DVM, MS, PhD

CEO & Scientific Director

Mauricio Bauer, DVM, BVSc.,MBA


Francisco Scacchetti, BBA

Chief Financial Officer

Bruce Truman

Strategic Adviser



505 S. Rosa Road, Suite 225

Madison, WI 53719